Targeting immune inhibitory molecules, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-1 (PD-1) and its ligand, PD-L1, aims to reinvigorate exhausted T cells, thus enabling improved tumor antigen recognition and cytotoxic activity (1). The gene discussed is CD274; the disease is neoplasm.